While EGFR-TKIs such as gefitinib, erlotinib, and osimertinib have revolutionized the treatment of EGFR-mutated NSCLC by targeting these mutations, therapeutic resistance remains a major challenge. Here, EGFR is linked to non-small cell lung carcinoma.